Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: KPT-330
Drug: Rituximab
Drug: Etoposide
Drug: Carboplatin
Drug: Ifosfamide
Drug: Dexamethasone

First Posted Date: 2015-06-15

Last Posted Date: 2022-04-12

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 22

Registration Number: NCT02471911

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Other: Placebo Administration
Other: Pharmacogenomic Study

First Posted Date: 2015-05-13

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT02443077

Locations: 🇺🇸
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States
🇺🇸
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
🇺🇸
Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States

and more 279 locations

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Drug: Ibrutinib
Drug: Rituximab
Drug: Gemcitabine
Drug: Dexamethasone
Drug: Mesna
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Selinexor
Drug: G-CSF

First Posted Date: 2015-05-07

Last Posted Date: 2024-06-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 320

Registration Number: NCT02436707

Locations: 🇨🇦
BCCA - Vancouver, Vancouver, British Columbia, Canada
🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 11 locations

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1

Completed

Conditions: Solid Malignant Tumors
Osteosarcoma
Differentiated Thyroid Cancer (DTC)
Tumors

Interventions: Drug: Lenvatinib
Drug: Ifosfamide
Drug: Etoposide

First Posted Date: 2015-05-04

Last Posted Date: 2023-07-11

Lead Sponsor: Eisai Limited

Target Recruit Count: 117

Registration Number: NCT02432274

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇫🇷
Centre Oscar Lambret Lille, Lille, Rhone, France
🇫🇷
CHU de Toulouse - Hopital des Enfants, Toulouse, France

and more 16 locations

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Phase 3

Recruiting

Conditions: Ovarian Germ Cell Cancer
Ovarian Neoplasms
Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Bleomycin
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2015-04-29

Last Posted Date: 2023-04-25

Lead Sponsor: Beihua Kong

Target Recruit Count: 129

Registration Number: NCT02429687

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors

Phase 3

Recruiting

Conditions: Ovarian Sex Cord Stromal Tumor
Ovarian Neoplasms
Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Bleomycin
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2015-04-29

Last Posted Date: 2023-04-25

Lead Sponsor: Beihua Kong

Target Recruit Count: 132

Registration Number: NCT02429700

Locations: 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Phase 1

Withdrawn

Conditions: Lymphoma
Hodgkin's Lymphoma
Non-hodgkin's Lymphoma

Interventions: Drug: Pembrolizumab
Drug: Brentuximab vedotin
Drug: Etoposide
Drug: Ifosfamide
Drug: Mesna
Drug: Carboplatin
Drug: Rituximab

First Posted Date: 2015-04-03

Last Posted Date: 2017-06-27

Lead Sponsor: Western Regional Medical Center

Registration Number: NCT02408042

Locations: 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Extensive Stage Small Cell Lung Carcinoma
Limited Stage Small Cell Lung Carcinoma
Neuroendocrine Neoplasm

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Procedure: Radiation Therapy

First Posted Date: 2015-03-30

Last Posted Date: 2024-11-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 83

Registration Number: NCT02402920

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Phase 1

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Crenolanib besylate
Drug: Idarubicin
Drug: Azacytidine
Drug: Cytarabine
Drug: Mitoxantrone
Drug: Etoposide
Drug: Fludarabine
Drug: G-CSF

First Posted Date: 2015-03-27

Last Posted Date: 2024-07-03

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 28

Registration Number: NCT02400281

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Phase 2

Recruiting

Conditions: Non-Hodgkin Lymphoma
Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Mediastinal B-cell Lymphoma
CD20+ Lymphoblastic Lymphoma
Follicular Lymphoma, Grade III

Interventions: Drug: Obinutuzumab
Drug: Liposomal ARA-C
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2015-03-19

Last Posted Date: 2023-10-26

Lead Sponsor: New York Medical College

Target Recruit Count: 25

Registration Number: NCT02393157

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy